NDA 219132 · Intrabio
Aqneursa
Levacetylleucine · Oral
NovelPriority reviewOrphanCDER novel approval, Sep 24, 2024: To treat Niemann-Pick disease type C
Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Sep 24, 2024
Approved uses
2
Original approval plus efficacy supplements
Registered trials
1
1 Phase 3, 0 recruiting
FAERS reports
251
63 serious, 14 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 13, 2026.
AQNEURSA is indicated for the treatment of: • neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg. ( 1.1 ) • ataxia in adults and pediatric patients with ataxia-telangiectasia (A-T) weighing ≥15 kg. ( 1.2 ) 1.1 Niemann-Pick Disease Type C AQNEURSA ® is indicated for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg. 1.2 Ataxia-Telangiectasia AQNEURSA is indicated for the treatment of ataxia in adults and pediatric patients with ataxia-telangiectasia (A-T) weighing ≥15 kg.
Mechanism: The distinct molecular target for levacetylleucine in the treatment of NPC or A-T is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 18, 2026 Supplement 2 · Efficacy · priority review OrphanLabelLetter
- Sep 24, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
- AQNEURSA · LEVACETYLLEUCINE 1GM/PACKET · FOR SUSPENSION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Levacetylleucine" as an intervention, any sponsor and status, largest first.
- A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)Pivotal-lookingActive, not recruiting
IntraBio IncIndustry
NCT06673056 · 60 participants (planned) · Start Mar 18, 2025 · Primary completion Dec 31, 2027
Drug: N-Acetyl-L-Leucine · For: Ataxia-Telangiectasia; Ataxia-Telangiectasia (A-T)
Sites: Los Angeles, California; Boston, Massachusetts; Houston, Texas · 11 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use140
- fall11
- product use in unapproved indication11
- seizure11
- vomiting9
- dysphagia8
- pneumonia8
- gait disturbance7
- pneumonia aspiration7
- decreased appetite6
- diarrhoea6
- product use issue6
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2023 | 1 |
| 2024 | 7 |
| 2025 | 151 |
| 2026 | 91 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Neurofilament light chain (NfL) as a surrogate outcome measure for GM2 gangliosidoses.
Martakis K, Abreu NJ, Baker JJ, et al. · J Neurol 2026 · Clinical Trial, Phase II, Multicenter Study
- Safety and efficacy of levacetylleucine in ataxia-telangiectasia: a phase 3, randomised, double-blind, placebo-controlled crossover trial.
Martakis K, Bremova-Ertl T, Bolton C, et al. · Lancet Neurol 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Pharmacological Interventions for Neurological Manifestations of Ataxia-Telangiectasia: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials.
Iqbal MJ, Azhar M, Hassan A, et al. · Cerebellum 2026 · Systematic Review, Meta-Analysis
Sponsor: Intrabio
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.